ORGANON ASIA PACIFIC SERVIECS PTE L.

Company Introduction: ORGANON ASIA PACIFIC SERVICES PTE L.

Organon is a global healthcare company focused on women's health. Organon Asia Pacific Services Pte L. in Singapore functions as the regional headquarters and a central service hub for Organon's operations across the Asia Pacific region.

This entity is primarily responsible for managing and supporting various regional business functions. These include developing and executing sales and marketing strategies, coordinating distribution networks, overseeing regulatory affairs, handling financial operations, and providing human resources and administrative support for Organon's pharmaceutical and healthcare products throughout the APAC market. Its role is crucial in ensuring the strategic growth and operational efficiency of Organon's business in the region.

Regarding whether it is a factory or a trader:

Organon Asia Pacific Services Pte L. is neither a factory (manufacturing plant) nor a traditional trading company. It operates as a regional service and administrative office, serving as the strategic and operational center for Organon's business activities in the Asia Pacific. It facilitates the commercialization and distribution of Organon's products but does not engage in direct manufacturing or act as an independent import/export trader.

ORGANON ASIA PACIFIC SERVIECS PTE L. in Singapore is involved in the sale and distribution of products from Organon's global portfolio. These products primarily include:

Contraceptives and Fertility Products: This category covers a range of options such as oral contraceptives, long-acting reversible contraceptives like subdermal implants and vaginal rings, and various fertility treatments including gonadotropins and GnRH antagonists.

Biosimilars: These are biologic medicines used to treat conditions such as autoimmune diseases and certain cancers.

Established Brands: This encompasses a broad range of pharmaceutical products across diverse therapeutic areas. These include medicines for cardiovascular conditions, respiratory issues, dermatological problems, and non-opioid pain management, many of which were part of Merck's legacy portfolio before Organon's spin-off.